Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients

References

• National Institute for Health and Clinical Excellence (NICE). Technology appraisal guidance 252. Telaprevir for the treatment of genotype 1 chronic hepatitis C. 2012. http://www.nice.org.uk/nicemedia/live/13717/58912/58912.pdf. Accessed September 6, 2012
   Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65
   PubMed Web of Science ®Google Scholar
• Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-44
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA). FDA approval of Incivek (telaprevir), a direct acting antiviral drug (DAA) to treat hepatitis C (HCV). 2011. http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm256328.htm. Accessed September 6, 2012
   Google Scholar
• US Food and Drug Administration (FDA). FDA approval of Victrelis (boceprevir), a direct acting antiviral drug (DAA) to treat hepatitis C (HCV). 2011. http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm255413.htm. Accessed September 6, 2012
   Google Scholar
• European Medicines Agency. INCIVO (telaprevir) EU Summary of Product Characteristics. EMEA, 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002313/WC500115529.pdf. Accessed September 6, 2012
   Google Scholar
• European Medicines Agency. VICTRELIS (boceprevir) EU Summary of Product Characteristics. EMEA, 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002332/WC500109786.pdf. Accessed September 6, 2012
   Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206
   PubMed Web of Science ®Google Scholar
• Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-44
   PubMed Web of Science ®Google Scholar
• Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127:855-65
   PubMed Web of Science ®Google Scholar
• Wright M, Grieve R, Roberts J, et al. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006;10:1-113, iii
   Web of Science ®Google Scholar
• Shepherd J, Jones J, Hartwell D, et al. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007;11:1-205, iii
   PubMed Web of Science ®Google Scholar
• Hartwell D, Jones J, Baxter L, et al. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess 2011;15:i-xii, 1-210
   Web of Science ®Google Scholar
• Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13.4:322-38
   Web of Science ®Google Scholar
• Grishchenko M, Grieve RD, Sweeting MJ, et al. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. Int J Technol Assess Health Care 2009;25:171-80
   PubMed Web of Science ®Google Scholar
• Grieve R, Roberts J, Wright M, et al. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 2006;55:1332-38
   PubMed Web of Science ®Google Scholar
• Fattovich G, Giustina G, Degos F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1997;27:201-5
   PubMed Web of Science ®Google Scholar
• Curtis L. Unit costs of Health and Social Care 2010. Personal Social Services Research Unit (PSSRU), University of Kent. 2010. http://www.pssru.ac.uk/project-pages/unit-costs/2010/index.php. Accessed September 6, 2012
   Google Scholar
• Joint Formulary Committee. British National Formulary. London: British Medical Association and Royal Pharmaceutical Society of Great Britain 9 A.D.No.58, 2011
   Google Scholar
• Prescription drug database and drug prescribing guide. Monthly Index of Medical Specialities [MIMS]. 2012. http://www.mims.co.uk/home/. Accessed January 2012
   Google Scholar
• MVH Group. The measurement and valuation of health. Final report on the modelling of valuation tariffs. Centre for Health Economics, University of York, 1995. http://www.york.ac.uk/che/publications/in-house/archive/1990s/. Accessed September 6, 2012
   Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108
   PubMed Web of Science ®Google Scholar
• Minami T, Kishikawa T, Sato M, et al. Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C. J Gastroenterol 2013;48:254-68
   Google Scholar
• Lee SS, Roberts SK, Berak H, et al. Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients. Liver Int 2012;32:1270-7
   PubMed Web of Science ®Google Scholar
• Cure S, Diels J, Gavart S, et al. Efficacy of telaprevir and boceprevir in treatment-naive and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis. Curr Med Res Opin 2012;28:1841-56
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. New Engl J Med 2009;360:1827-38
   PubMed Web of Science ®Google Scholar
• Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. New Engl J Med 2009;360:1839-50
   PubMed Web of Science ®Google Scholar
• Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010;376:705-16
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93
   PubMed Web of Science ®Google Scholar
• Rumi MG, Aghemo A, Prati GM, et al. Randomized Study of Peginterferon-alpha2a Plus Ribavirin vs Peginterferon-alpha2b Plus Ribavirin in Chronic Hepatitis C. Gastroenterology 2010;138:108-15
   PubMed Web of Science ®Google Scholar
• Yenice N, Mehtap O, Gumrah M, et al. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turk J Gastroenterol 2006;17:94-8
   PubMedGoogle Scholar
• National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisals. 2008
   Google Scholar
• Rauch A, Rohrbach J, Bochud PY. The recent breakthroughs in the understanding of host genomics in hepatitis C. Eur J Clin Invest 2010;40:950-9
   PubMed Web of Science ®Google Scholar
• Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9
   PubMed Web of Science ®Google Scholar
• Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-4
   PubMed Web of Science ®Google Scholar
• Camma C, Di BD, Schepis F, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004;39:333-42
   PubMed Web of Science ®Google Scholar
• Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13
   PubMed Web of Science ®Google Scholar
• George SL, Bacon BR, Brunt EM, et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009;49:729-38
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28
   PubMed Web of Science ®Google Scholar
• Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-24. Erratum in: N Engl J Med 2011;365:1551
   PubMed Web of Science ®Google Scholar
• Sullivan JC, De Meyer S, Bartels DJ, et al. Evolution of treatment-emergent variants in telaprevir phase 3 clinical trials. In: 46th Annual Meeting of the European Association for the Study of the Liver; 2011 Mar 30-Apr 2; Berlin. J Hepatol 2011;54(1 Suppl):S4
   Google Scholar
• Zeuzem S, Sulkowski MS, Zoulim F, et al. Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis from the EXTEND study. In: 61st Annual Meeting of the American Association for the Study of Liver Diseases; 2010 Oct 29-Nov 2; Boston, MA. Hepatology 2010;52(Suppl):436A
   Google Scholar
• Sarrazin C, Reesnik HW, Zeuzem S, et al. Retreatment with telaprevir/PEG-IFN/RBV after a short exposure to telaprevir in phase I studies: interim results from a phase IIIB rollover trial (C219). In: 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 2011 Nov 5-8; San Francisco, CA. Hepatology 2011;54(1Suppl):377A
   Google Scholar
• United States Centers for Disease Control and Prevent (CDC). CDC announces first ever national hepatitis testing day and proposes that all baby boomers be tested once for hepatitis C. http://www.cdc.gov/nchhstp/newsroom/HepTestingRecsPressRelease2012.html. Accessed September 6, 2012
   Google Scholar
• Poret W, Ozminkowski J, Goetzel R, et al. Cost Burden of illness for Hepatitis C patients with employer-sponsored health insurance. Dis Manag 2002;5:95-107
   Google Scholar
• Singal AG, Volk ML, Jensen D, et al. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010;8:280-8
   PubMed Web of Science ®Google Scholar
• Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007;45:579-87
   PubMed Web of Science ®Google Scholar
• Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677-84
   PubMed Web of Science ®Google Scholar